Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.
ABBV Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for ABBV, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that AbbVie Inc ranked in the 72th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 226%. In terms of the factors that were most noteworthy in this DCF analysis for ABBV, they are:
The stock's equity weight, or the proportion of capital from equity relative to debt, is 68. Notably, its equity weight is greater than just 21.17% of US equities in the Healthcare sector yielding a positive free cash flow.
AbbVie Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than just 7.91% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of AbbVie Inc? See ALXN, FTLF, ARA, VTRS, and HUM.
Regenxbio announces expansion of RGX-121 clinical program Regenxbio Inc. (RGNX) announced the expansion of its Mucopolysaccharidosis Type II clinical program. The company stated that the expansion will allow it to gain additional understanding of the neurodegenerative aspects of the disease. The expansion will also let Regenxbio in a broader patients...
Avisol Capital Partners on Seeking Alpha | October 3, 2020
The research report on Pain Management Market provides a comprehensive analysis of the market status and development trend, including types, applications, growth, opportunities, rising technology, competitive landscape and product offerings of key players. Pain Management Market report covers the present
AbbVie ([[ABBV]] +1.3%) unit Allergan, along with Health Canada, is voluntarily withdrawing Fibristal (ulipristal acetate tablets, 5 mg) from the Canadian market following reports from Europe of rare cases of liver injury requiring transplantation.FIBRISTAL is approved in Canada for preoperative treatment of moderate-to-severe signs and symptoms of uterine fibroids in adult women of...